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ABSTRACT 
Background and aims: The term hemophagocytic lymphohistiocytosis (HLH) comprises two main 
disease entities: the primary, familial form (FHL) and an acquired, secondary form (sHLH). FHL is 
autosomal recessive in inheritance, typically affects very young children and is almost invariably 
fatal unless treated. Secondary HLH typically occurs in older children and adults. However, sHLH 
may also affect infants and FHL may affect adults. In the absence of reliable functional cell studies, 
a genetic diagnosis or a family history of HLH, differentiation between the two at onset is virtually 
impossible. Other inherited syndromes in which HLH can develop are X-linked lymphoproliferative 
disease (XLP), Chédiak-Higashi syndrome (CHS), and Griscelli syndrome type II (GS2). HLH 
signs and symptoms are related to hyperinflammation after a triggering infection, and include 
persisting fever, hepatosplenomegaly and non-malignant infiltration in many organs, including bone 
marrow, liver, spleen and central nervous system (CNS) of activated T lymphocytes and 
macrophages, the latter involved in hemophagocytosis. Neurological symptoms can be present 
already at onset. Laboratory investigations typically reveal cytopenia, elevated values of liver 
enzymes, ferritin, cytokines and triglycerides, and a coagulopathy. In FHL, natural killer cells are 
normal in number but show reduced or absent function. 
 
The aims of this thesis include description of disease characteristics at onset as well as presentation 
of treatment results prior to and after hematopoietic stem cell transplant (HSCT) in children with 
HLH (Paper I), and in the other inherited HLH-related diseases (Paper III). Furthermore, the aims 
include description of the frequency and character of acute CNS disease and of CNS sequelae 
(Paper II), and to evaluate risk factors for adverse outcome (Papers II, IV and V). 
 
Methods: The studies were conducted on data from patients recruited from the databases of the 
international treatment study protocols HLH-94 (paper I, n=249; paper II, n=193) and HLH-2004 
(paper V, n=297). In paper III patients were recruited from both protocols. In paper IV, the data 
were collected as part of a European collaborative effort. 
 
Results: At a median follow-up of 6 years, overall 5-year probability of survival in the HLH-94 
treatment study was 55%, and 5-year survival post-transplant was 67%. Altogether, 73% of the 
patients received transplants or achieved long-term remission without HSCT. There was no 
significant difference in survival for patients with familial disease. Patients with a presumed 
secondary disease were older, more often female, and less frequently had CNS disease at onset 
(paper I). CNS disease at onset was common, (63%) and an important risk factor for both death and 
neurological late effects. Neurological sequelae were present in 15% upon follow-up (paper II). 
Seven of nine patients with GS2, XLP or CHS could receive transplants after HLH therapy, and one 
had long-term remission without HSCT. At last follow-up (mean 6 years), eight of nine were alive 
(paper III). Risk factors for early pre-transplant death that remained significant in both papers IV 
and V were hyperbilirubinemia at onset and hyperferritinemia and thrombocytopenia after two 
weeks. 
 
Conclusion: In conclusion, survival has increased dramatically in patients with HLH with the 
introduction of the HLH-94 treatment protocol, but a large proportion of patients still succumb to 
the disease. Novel treatment strategies need to be developed in order to reduce early pre-transplant 
mortality, but also to reduce transplant-related mortality and morbidity. CNS-HLH is frequent, and 
a risk-factor for adverse outcome. Thorough evaluation of acute CNS symptoms and signs, as well 
as close neurological follow-up is important. Patients with HLH-associated syndromes may also 
benefit from HLH-94 treatment. There are simple laboratory parameters that may help in risk 
estimation of HLH patients, and these - alone or taken together - may be used to adapt treatment 
intensity. 
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